Assessment of the dynamics of immunological parameters at the beginning of therapy as prognostic and predictive factors in patients with melanoma
- Autores: Novik A.V1,2, Danilova A.B1, Nekhaeva T.L1, Emelyanova N.V1, Semenova A.I1, Latipova D.K.1, Teletaeva G.M1, Protsenko S.A1, Baldueva I.A1
-
Afiliações:
- N.N. Petrov National Medical Research Center of Oncology
- Saint Petersburg State Pediatric Medical University
- Edição: Volume 28, Nº 7 (2021)
- Páginas: 118-126
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313188
- DOI: https://doi.org/10.18565/pharmateca.2021.7.118-126
- ID: 313188
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
A. Novik
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University
Email: anovik@list.ru
Saint Petersburg, Russia
A. Danilova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
T. Nekhaeva
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
N. Emelyanova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
A. Semenova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
D. Latipova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
G. Teletaeva
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
S. Protsenko
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
I. Baldueva
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
Bibliografia
- Suda K. Recent Advances in Cancer Immunotherapy. Biomolecules. 2021;11(2):335. Doi: 10.3390/ biom11020335
- Griffiths J.I., Wallet P., Pflieger L.T., et al. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A. 2020;117(27):16072-82. Doi: 10.1073/ pnas.1918937117.
- Новик А.В., Гирдюк Д.В., Кузнецова А.И. и др. Способ определения значимости различий результатов измерения субпопуляции лимфоцитов методом проточной цитофлюориметрии. Патент № RU 2720411 C1 от 29.04.2020.
- Fennemann F.L., de Vries I.J. M., Figdor C.G., et al. Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. Front Immunol. 2019:10:824. doi: 10.3389/fimmu.2019.00824.
- de Coana Y.P, Wolodarski M., Poschke I., et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017;8(13):21539-53. doi: 10.18632/oncotarget.15368.
- Carnevalli L.S., Ghadially H., Barry S.T. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. Front Immunol. 2021;12:633685. Doi: 10.3389/ fimmu.2021.633685.
- Huntington N.D., Cursons J., Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer. 2020;20(8):437-54. doi: 10.1038/s41568-020-0272-z.
- Foureau D.M., Amin A., White R.L., et al. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome. Cancer Immunol Immunother. 2014;63(12):1329-1340. Doi: 10.1007/ s00262-014-1605-0.
- Новик А.В., Проценко С.А., Балдуева И.А. Использование оценки состояния врожденной иммунной системы у больных со злокачественными солидными опухолями в качестве предиктивных или прогностических факторов: систематический обзор Эффективная фармакотерапия. 2020;16(8):58-77.
- Coffelt S.B., Wellenstein M.D. de Visser K.E. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431-46. Doi: 10.1038/ nrc.2016.52.
- Shaul M.E., Fridlender Z.G. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601-20. Doi: 10.1038/ s41571-019-0222-4.
- Ouwerkerk W, van den Berg M, van der Niet S, et al. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Res. 2019;29(5):453-64. doi: 10.1097/CMR.0000000000000589.